RSV prefusion F protein (subgroups A and B) · RSV
Health Canada DIN 02544040. Check the product and formulation on your record before using a schedule.
Plan doses for this product →This vaccine helps protect against serious lung infections caused by respiratory syncytial virus (RSV).
ABRYSVO is listed under Health Canada DIN 02544040. The product record and monograph below describe this formulation; the dose schedule comes from the Canadian Immunization Guide.
02544040Age and suitability depend on the product, the person and the reason for vaccination. Use the planner for a starting point and confirm with a healthcare professional.
Use the DIN to confirm this exact product in Health Canada's Drug Product Database.
A listed product may not be stocked or publicly funded.
These steps come from the Canadian Immunization Guide's administration practices and acute reactions guidance.
The details below are adapted from a Pharmasist patient handout linked to the same product monograph. The current Canadian Immunization Guide determines the dose schedules shown later.
The practical points are adapted from the Pharmasist reference for ABRYSVO and its matching product monograph.
These are Canadian Immunization Guide schedules associated with this DIN. The right schedule depends on age, health, prior doses and reason for vaccination. Public health recommendations may differ from a product monograph's authorized schedule.
One dose of RSV vaccine is recommended for all adults 75 years of age and older.
NACI recommends a single dose of RSV vaccine (AREXVY, ABRYSVO or MRESVIA) for all adults 75 years of age and older. Protection lasts at least 3 years; no repeat dose is currently recommended.
One dose is recommended for adults 65 to 74 with a condition that raises the risk of severe RSV disease.
NACI recommends a single dose for adults 65 to 74 who are at increased risk: chronic heart or lung disease (including COPD, asthma, cystic fibrosis), diabetes and metabolic disease, moderate or severe immunodeficiency, chronic kidney or liver disease, neurologic or neurodevelopmental conditions, class 3 obesity, or residence in a nursing home. Other adults 65 to 74 may consider it.
One dose is recommended for the highest-risk adults 18 and older, and may be considered for other adults at increased risk.
NACI recommends a single dose for adults 18 and older who live in a nursing home, have had a lung or stem-cell transplant, are on home oxygen or receive dialysis. Other adults 18 to 64 at increased risk of severe RSV disease may consider a single dose. AREXVY is authorized from 50 years; ABRYSVO and MRESVIA from 18.
One dose of ABRYSVO during pregnancy to protect the newborn; NACI recommends 28 to 36 weeks, the product is authorized for 32 to 36 weeks.
ABRYSVO only. NACI recommends one dose at 28 to 36 weeks of gestation, before or during the RSV season, at least 2 weeks before birth; Health Canada authorizes 32 to 36 weeks. There is no recommendation for a repeat dose in a later pregnancy; the infant can receive a monoclonal antibody instead.
Family guidance on pregnancy: ABRYSVO is recommended at 28 to 36 weeks of gestation, before or during RSV season (Health Canada authorizes 32 to 36 weeks). AREXVY and MRESVIA are not used in pregnancy.
Family guidance on breastfeeding: Not recommended on the basis of breastfeeding alone; the maternal dose protects the infant when given during pregnancy.
This guidance applies to the vaccine family. Confirm this product's details in the monograph and with your clinician. Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026.
General information only. A suggested date is not an appointment or a prescription; a healthcare professional confirms what you need. Clinical rules reviewed on 2026-09-27.
Explore care options